ReciBioPharm expand collaboration with University of Oxford
The University of Oxford and ReciBioPharm, Recipharm’s Advanced Biologics division are expanding their collaboration with the development of two blood-stage malaria vaccine candidates for Phase 1/2 clinical trials.
June 9, 2025
Since 2016, this collaboration has delivered five vaccine candidates and will now actively progress the manufacture of R78C and RH5.1 for the University’s Draper Lab, based at the Department of Paediatrics.
World Malaria Day 2025: The ongoing challenge of putting an end to malaria
In 2023, there were an estimated 263 million malaria cases, and 597,000 malaria deaths, making it a prioritized field for many researchers around the world. In Umeå, Sweden, Professor Oliver Billker’s group is focusing on the basic biology of the parasite, with the goal to develop new drugs and vaccines and understand why some mosquito species transmit malaria while others do not.
ReciBioPharm initially produced both the drug substance and drug product for R78C and is now handling large scale fill and finish activities to meet increased vial demand for ongoing trials. Additionally, RH5.1, previously manufactured by another CDMO, is now being fully produced by ReciBiopharm, including drug substance, drug product and large-scale fill and finish.
“We’re proud to deepen our collaboration with the University of Oxford on such a critical global health challenge. Our ability to deliver drug substance and drug product for larger scales under GMP conditions makes us a strong partner for accelerating vaccine candidates from lab to clinic. Together, we’re advancing science with the potential to save millions of lives,” says Greg Behar, CEO of Recipharm.
Published: June 9, 2025
